C1orf50 Drives Malignant Melanoma Progression Through the Regulation of Stemness.

IF 2.6 4区 医学 Q2 GENETICS & HEREDITY
Yusuke Otani, Masaki Maekawa, Atsushi Tanaka, Tirso Peña, Vanessa D Chin, Anna Rogachevskaya, Shinichi Toyooka, Michael H Roehrl, Atsushi Fujimura
{"title":"C1orf50 Drives Malignant Melanoma Progression Through the Regulation of Stemness.","authors":"Yusuke Otani, Masaki Maekawa, Atsushi Tanaka, Tirso Peña, Vanessa D Chin, Anna Rogachevskaya, Shinichi Toyooka, Michael H Roehrl, Atsushi Fujimura","doi":"10.21873/cgp.20518","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Recent advancements in omics analysis have significantly enhanced our understanding of the molecular pathology of malignant melanoma, leading to the development of novel therapeutic strategies that target specific vulnerabilities within the disease. Despite these improvements, the factors contributing to the poor prognosis of patients with malignant melanoma remain incompletely understood. The aim of this study was to investigate the role of <i>C1orf50</i> (Chromosome 1 open reading frame 50), a gene previously of unknown function, as a prognostic biomarker in melanoma.</p><p><strong>Materials and methods: </strong>We performed comprehensive transcriptome data analysis and subsequent functional validation of the human Skin Cutaneous Melanoma project from The Cancer Genome Atlas (TCGA).</p><p><strong>Results: </strong>Elevated expression levels of <i>C1orf50</i> correlated with worse survival outcomes. Mechanistically, we revealed that C1orf50 plays a significant role in the regulation of cell cycle processes and cancer cell stemness, providing a potential avenue for novel therapeutic interventions in melanoma.</p><p><strong>Conclusion: </strong>This study is the first to identify <i>C1orf50</i> as a prognostic biomarker in melanoma. The clinical relevance of our results sheds light on the importance of further investigation into the biological mechanisms underpinning C1orf50's impact on melanoma progression and patient prognosis.</p>","PeriodicalId":9516,"journal":{"name":"Cancer Genomics & Proteomics","volume":"22 4","pages":"510-524"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genomics & Proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/cgp.20518","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: Recent advancements in omics analysis have significantly enhanced our understanding of the molecular pathology of malignant melanoma, leading to the development of novel therapeutic strategies that target specific vulnerabilities within the disease. Despite these improvements, the factors contributing to the poor prognosis of patients with malignant melanoma remain incompletely understood. The aim of this study was to investigate the role of C1orf50 (Chromosome 1 open reading frame 50), a gene previously of unknown function, as a prognostic biomarker in melanoma.

Materials and methods: We performed comprehensive transcriptome data analysis and subsequent functional validation of the human Skin Cutaneous Melanoma project from The Cancer Genome Atlas (TCGA).

Results: Elevated expression levels of C1orf50 correlated with worse survival outcomes. Mechanistically, we revealed that C1orf50 plays a significant role in the regulation of cell cycle processes and cancer cell stemness, providing a potential avenue for novel therapeutic interventions in melanoma.

Conclusion: This study is the first to identify C1orf50 as a prognostic biomarker in melanoma. The clinical relevance of our results sheds light on the importance of further investigation into the biological mechanisms underpinning C1orf50's impact on melanoma progression and patient prognosis.

C1orf50通过干细胞调控推动恶性黑色素瘤的进展。
背景/目的:组学分析的最新进展显著增强了我们对恶性黑色素瘤分子病理学的理解,导致针对该疾病特定脆弱性的新治疗策略的发展。尽管有这些改善,导致恶性黑色素瘤患者预后不良的因素仍然不完全清楚。本研究的目的是研究C1orf50(1号染色体开放阅读框50)的作用,这是一个功能未知的基因,作为黑色素瘤的预后生物标志物。材料和方法:我们对来自癌症基因组图谱(TCGA)的人类皮肤黑色素瘤项目进行了全面的转录组数据分析和随后的功能验证。结果:C1orf50表达水平升高与较差的生存结果相关。在机制上,我们揭示了C1orf50在细胞周期过程和癌细胞干细胞性的调节中发挥重要作用,为黑色素瘤的新治疗干预提供了潜在的途径。结论:本研究首次确定了c10f50作为黑色素瘤的预后生物标志物。我们的结果的临床相关性揭示了进一步研究支撑c10f50对黑色素瘤进展和患者预后影响的生物学机制的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Genomics & Proteomics
Cancer Genomics & Proteomics ONCOLOGY-GENETICS & HEREDITY
CiteScore
5.00
自引率
8.00%
发文量
51
期刊介绍: Cancer Genomics & Proteomics (CGP) is an international peer-reviewed journal designed to publish rapidly high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research. In this site you may find information concerning the editorial board, editorial policy, issue contents, subscriptions, submission of manuscripts and advertising. The first issue of CGP circulated in January 2004. Cancer Genomics & Proteomics is a journal of the International Institute of Anticancer Research. From January 2013 CGP is converted to an online-only open access journal. Cancer Genomics & Proteomics supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信